Literature DB >> 21404144

Actovegin®: a biological drug for more than 5 decades.

Florian Buchmayer1, Johannes Pleiner, Martin W Elmlinger, Gereon Lauer, Gerfried Nell, Harald H Sitte.   

Abstract

Actovegin(®) is a biological drug manufactured from a natural source: it is a calf blood hemodialysate. Its therapeutic benefits stem from a variety of pharmacodynamic actions that can be summarized to a common goal, i.e. the enhancement of cellular metabolism; this results from an insulin-like activity mediated by Inositol-phospho-oligosaccharides. Actovegin(®) results in beneficial effects in several pathophysiological clinical settings including malfunction of the blood circulation and trophic disturbances in the brain, impairment of peripheral blood circulation and associated diseases, dermal transplants and acute and chronic wounds. Here, we give an overview of the pharmacodynamic actions of calf-blood hemidialysate and its beneficial effects in a variety of clinical settings.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21404144     DOI: 10.1007/s10354-011-0865-y

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  36 in total

1.  [Pharmacological effect of Solcoseryl on the metabolism of the brain. Animal experiments and clinical research].

Authors:  G Lanner
Journal:  Wien Med Wochenschr       Date:  1975-11-21

2.  Evidence for a factor protective against hypoxic liver parenchymal cell injury in a protein-free blood extract.

Authors:  H de Groot; M Brecht; F Machicao
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1990-04

3.  Differential protection of radiation-induced DNA single-strand breaks and cell survival by solcoseryl.

Authors:  C P Sigdestad; K W Doak; D J Grdina
Journal:  Experientia       Date:  1988-08-15

4.  [Cardiotonic effect of blood extracts on myocardial tissue].

Authors:  K Eichler; R Völker
Journal:  Arzneimittelforschung       Date:  1971-11

5.  Evaluation of some radioprotectors by the survival study of rats exposed to lethal dose of whole body gamma radiation.

Authors:  S K Basu; M N Srinivasan; K Chuttani; A Ghose
Journal:  J Radiat Res       Date:  1985-12       Impact factor: 2.724

6.  Inositol glycan mimics the action of insulin on glucose utilization in rat adipocytes.

Authors:  A R Saltiel; L R Sorbara-Cazan
Journal:  Biochem Biophys Res Commun       Date:  1987-12-31       Impact factor: 3.575

7.  Protection from hypoxic injury in cultured hepatocytes by glycine, alanine, and serine.

Authors:  M Brecht; H de Groot
Journal:  Amino Acids       Date:  1994-02       Impact factor: 3.520

8.  The effects of a deproteinized blood extract on the myocardial changes developing during experimentally induced intermittent hypoxia.

Authors:  E Somogyi; P Sótonyi; A Nemes
Journal:  Arzneimittelforschung       Date:  1979

9.  Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.

Authors:  Dan Ziegler; Lusine Movsesyan; Boris Mankovsky; Irina Gurieva; Zhangentkhan Abylaiuly; Igor Strokov
Journal:  Diabetes Care       Date:  2009-05-26       Impact factor: 17.152

View more
  9 in total

1.  Actovegin reduces the ROS level in blood samples of heart failure patients and diminishes necrosis of SK-N-SH human neuroblastoma cells.

Authors:  E I Astashkin; M G Glezer; M G Vinokurov; N D Egorova; N S Orekhova; A N Novikova; S V Grachev; M M Yurinskaya; K E Sobolev
Journal:  Dokl Biol Sci       Date:  2013-03-12

2.  Actovegin in the management of patients after ischemic stroke: A systematic review.

Authors:  Philip la Fleur; Ardak Baizhaxynova; Emily Reynen; David Kaunelis; Dinara Galiyeva
Journal:  PLoS One       Date:  2022-06-30       Impact factor: 3.752

3.  Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro.

Authors:  Martin W Elmlinger; Martin Kriebel; Dan Ziegler
Journal:  Neuromolecular Med       Date:  2011-10-09       Impact factor: 3.843

4.  Treatment with Actovegin improves spatial learning and memory in rats following transient forebrain ischaemia.

Authors:  Sigal Meilin; Fausto Machicao; Martin Elmlinger
Journal:  J Cell Mol Med       Date:  2014-05-06       Impact factor: 5.310

5.  Current Synthesis and Systematic Review of Main Effects of Calf Blood Deproteinized Medicine (Actovegin®) in Ischemic Stroke.

Authors:  Florentina Carmen Firan; Aurelia Romila; Gelu Onose
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

Review 6.  Growth factors for treating diabetic foot ulcers.

Authors:  Arturo J Martí-Carvajal; Christian Gluud; Susana Nicola; Daniel Simancas-Racines; Ludovic Reveiz; Patricio Oliva; Jorge Cedeño-Taborda
Journal:  Cochrane Database Syst Rev       Date:  2015-10-28

7.  A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design.

Authors:  Alla Guekht; Ingmar Skoog; Amos D Korczyn; Vladimir Zakharov; Martin Eeg; Ulf Vigonius
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2013-12-14

8.  ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.

Authors:  Alla Guekht; Ingmar Skoog; Sally Edmundson; Vladimir Zakharov; Amos D Korczyn
Journal:  Stroke       Date:  2017-05       Impact factor: 7.914

9.  Intramuscular Injection of Combined Calf Blood Compound (CFC) and Homeopathic Drug Tr14 Accelerates Muscle Regeneration In Vivo.

Authors:  Patrick Belikan; Lisa Nauth; Lars-Christopher Färber; Frédéric Abel; Eva Langendorf; Philipp Drees; Pol Maria Rommens; Ulrike Ritz; Stefan G Mattyasovszky
Journal:  Int J Mol Sci       Date:  2020-03-19       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.